Clinical trials: Prognostic
Gastroenteropancreatic Neuroendocrine Tumors
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut…
- Trial name
- EXPLAIN (NCT02630654)
- Testing
- This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
- Where
- 25 sites in Denmark, Estonia and 5 more
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Ipsen
Colorectal Cancer in Patients Under 50 Years of Age, Colorectal Cancer
Colorectal Cancer in Young Adults: Study of Incidence, Survival, and Prognostic Factors in Tarragona, Spain
We conducted an observational, descriptive, longitudinal and retrospective study of 59 patients under 50 years of age diagnosed with CRC in the province of Tarragona, between 2019 and 2024.
- Trial name
- CCR50 (NCT07026955)
- Testing
- colorectal cancer in patients over 50 years of age
- Where
- Spain
- Volunteers
- 59 people
- Sponsor
- HJ23
Rheumatoid Arthritis
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
The objective of this study is to assess the efficacy of certolizumab pegol (CZP) with methotrexate (MTX) compared with MTX-alone in patients with early-stage rheumatoid arthritis (RA) who are naive to MTX and have with poor…
- Trial name
- NCT01451203
- Testing
- CZP, methotrexate (MTX)
- Where
- 8 sites in Japan
- Volunteers
- 319 people
- Sponsor
- Astellas Pharma Inc
Myelodysplastic Syndrome
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
The purpose of this randomized, double-blind, placebo-controlled study is to determine the safety and efficacy of pracinostat compared to placebo when combined with azacitidine, and FDA approved treatment for Myelodysplastic…
- Trial name
- NCT01873703
- Testing
- pracinostat, Azacitidine
- Where
- 24 sites in United States
- Volunteers
- 102 people
- Sponsor
- Helsinn Healthcare SA
Epilepsy
A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy
This multisite prospective clinical study is to investigate the relationship between seizure type and frequency with the BioEP result during ASM titration in newly diagnosed patients with epilepsy, and to assess the utility of…
- Trial name
- ECLIPSE (NCT06354868)
- Volunteers
- 158 people
- Sponsor
- Neuronostics Ltd
Diffuse B-Cell Lymphoma
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
This is Phase 1/2 study of avadomide (CC-122) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, for first-line treatment of patients with Diffuse B-Cell Large B-Cell…
- Trial name
- NCT03283202
- Testing
- Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 35 people
- Sponsor
- Celgene
Myelodysplastic Syndrome (MDS)
Darbepoetin Alfa MDS Companion Protocol
The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 (NCT01362140) study for…
- Trial name
- NCT02175277
- Testing
- Darbepoetin Alfa
- Where
- 4 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- Amgen
Knee Osteoarthritis
Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis
The purposes of this study are to assess the prognostic value of serum and urinary biomarkers Coll2-1 and Coll2-1NO2 at baseline, and their change over the first year, on the progression of knee osteoarthritis MRI scores at 12…
- Trial name
- PRODIGE (NCT02070224)
- Testing
- Serum and urine samples collections, Imaging (x-rays and MRI)
- Where
- 2 sites in Belgium, France
- Volunteers
- 120 people
- Sponsor
- Artialis
Multiple Sclerosis
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
This is a prospective, multicenter, observational, non-interventional study (NIS) in patients with Multiple Sclerosis (MS) and routinely assessed serum neurofilament light (sNfL) values in Germany
- Trial name
- FILAXOS (NCT06551519)
- Testing
- ofatumumab, DMT category 1
- Where
- 82 sites in Germany
- Volunteers
- 519 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure (HF)
Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.
This aim of the study is to investigate the prognostic usefulness of AdreView™ imaging to identify those subjects with New York Heart Association (NYHA) Class II or III HF who will die during 60 months of follow-up from the date…
- Trial name
- NCT02127307
- Where
- United States
- Volunteers
- 964 people
- Sponsor
- GE Healthcare
Infertility
A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation
This is a phase IV non-interventional, multicentric observational study to evaluate the baseline follicle stimulating hormone (FSH) levels, ovarian volume, antral follicle count (AFC) and age as prognostic factors of the outcome…
- Trial name
- NCT01196143
- Where
- Greece
- Volunteers
- 356 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
HER2-negative
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients
This noninterventional, multicenter,retrospective study has been proposed to estimate the prevalence, clinicopathological characteristics,treatment patterns and clinical outcomes of human epidermal growth factor receptor 2…
- Trial name
- iRetroBC (NCT06131424)
- Where
- 31 sites in Argentina, Brazil and 11 more
- Volunteers
- 1,151 people
- Sponsor
- AstraZeneca
Primary Myelofibrosis
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- NCT04446650
- Testing
- Fedratinib
- Where
- 21 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease
Prognostic Assessment of Contrast Echocardiography (PACE Study)
This study will demonstrate whether patients with prognostically-significant myocardial abnormalities detected with AI-700 contrast ECHO have a rate of cardiac death or MI that is higher than that of patients with normal AI-700…
- Trial name
- PACE (NCT00670332)
- Where
- United States
- Volunteers
- 773 people
- Sponsor
- Acusphere
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving…
- Trial name
- NCT01724294
- Where
- Romania
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndrome
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk…
- Trial name
- NCT02706899
- Testing
- vadastuximab talirine, Azacitidine
- Where
- 34 sites in United States
- Volunteers
- 19 people
- Sponsor
- Seagen Inc.
Barrett Esophagus, Esophageal Cancer
Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus
Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different…
- Trial name
- NCT05846971
- Testing
- Educational materials on validated methylation assay
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Capsulomics, Inc.
Breast Cancer Female, Stage II Breast Cancer
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.
- Conditions
- Breast Cancer Female, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
- Trial name
- BRAVA (NCT06087120)
- Where
- 3 sites in Indonesia, Vietnam
- Volunteers
- 125 people
- Sponsor
- Gene Solutions
Critically Ill Patients
Continuous Glucose Monitoring System: Accuracy and Prognostic Value in Critically Ill Patients
Whether diabetic or non-diabetic patients, blood glucose management during ICU hospitalization is essential. This study aims to evaluate the accuracy of the iCan Continuous Glucose Monitoring (CGM) System for detecting blood…
- Trial name
- NCT07108179
- Testing
- Continuous Glucose Monitoring (CGM) System
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sinocare
Heart Failure, Congestive
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
- Trial name
- NCT00126425
- Testing
- 123I-mIBG (meta-iodobenzylguanidine)
- Where
- United States
- Volunteers
- 587 people, healthy volunteers welcome
- Sponsor
- GE Healthcare